IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v46y2023i9d10.1007_s40264-023-01329-w.html
   My bibliography  Save this article

Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study

Author

Listed:
  • Michele Fusaroli

    (University of Bologna)

  • Francesco Salvo

    (Univ. Bordeaux, INSERM, BPH, U1219, Team AHeaD
    CHU de Bordeaux, Pôle de Santé Publique, Service de Pharmacologie Médicale)

  • Claire Bernardeau

    (Grenoble Alpes University Hospital)

  • Maryam Idris

    (Univ. Bordeaux, INSERM, BPH, U1219, Team AHeaD)

  • Charles Dolladille

    (UNICAEN, EA4650 SEILIRM, CHU de Caen Normandie, Normandie University
    CHU de Caen Normandie)

  • Antoine Pariente

    (Univ. Bordeaux, INSERM, BPH, U1219, Team AHeaD
    CHU de Bordeaux, Pôle de Santé Publique, Service de Pharmacologie Médicale)

  • Elisabetta Poluzzi

    (University of Bologna)

  • Emanuel Raschi

    (University of Bologna)

  • Charles Khouri

    (Grenoble Alpes University Hospital
    Univ. Grenoble Alpes, HP2 Laboratory, Inserm U1300)

Abstract

Background and Aim Disproportionality analysis is traditionally used in spontaneous reporting systems to generate working hypotheses about potential adverse drug reactions: the so-called disproportionality signals. We aim to map the methods used by researchers to assess and increase the validity of their published disproportionality signals. Methods From a systematic literature search of published disproportionality analyses up until 1 January 2020, we randomly selected and analyzed 100 studies. We considered five domains: (1) rationale for the study, (2) design of disproportionality analyses, (3) case-by-case assessment, (4) use of complementary data sources, and (5) contextualization of the results within existing evidence. Results Among the articles, multiple strategies were adopted to assess and enhance the results validity. The rationale, in 95 articles, was explicitly referred to the accrued evidence, mostly observational data (n = 46) and regulatory documents (n = 45). A statistical adjustment was performed in 34 studies, and specific strategies to correct for biases were implemented in 33 studies. A case-by-case assessment was complementarily performed in 35 studies, most often by investigating temporal plausibility (n = 26). Complementary data sources were used in 25 articles. In 78 articles, results were contextualized using accrued evidence from the literature and regulatory documents, the most important sources being observational (n = 45), other disproportionalities (n = 37), and case reports (n = 36). Conclusions This meta-research study highlighted the heterogeneity in methods and strategies used by researchers to assess the validity of disproportionality signals. Mapping these strategies is a first step towards testing their utility in different scenarios and developing guidelines for designing future disproportionality analysis.

Suggested Citation

  • Michele Fusaroli & Francesco Salvo & Claire Bernardeau & Maryam Idris & Charles Dolladille & Antoine Pariente & Elisabetta Poluzzi & Emanuel Raschi & Charles Khouri, 2023. "Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study," Drug Safety, Springer, vol. 46(9), pages 857-866, September.
  • Handle: RePEc:spr:drugsa:v:46:y:2023:i:9:d:10.1007_s40264-023-01329-w
    DOI: 10.1007/s40264-023-01329-w
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-023-01329-w
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-023-01329-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:46:y:2023:i:9:d:10.1007_s40264-023-01329-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.